Mark A. Socinski, MD

Overview

Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.

Articles

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

JOURNAL OF THORACIC ONCOLOGY

2022

['Poziotinib in Non-Small-Cell Lung Cancer Harboring', 'Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.']

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

EXPERT OPINION ON INVESTIGATIONAL DRUGS

2022

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

NATURE MEDICINE

2022

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

JOURNAL OF CLINICAL ONCOLOGY

2022

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

JOURNAL FOR IMMUNOTHERAPY OF CANCER

2022

Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

ANNALS OF ONCOLOGY

2021

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

FRONTIERS IN ONCOLOGY

2021

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).

JOURNAL OF CLINICAL ONCOLOGY

2021

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer ABOUND.sqm): A Phase III Randomized Clinical Trial

CLINICAL LUNG CANCER

2021

Associated Clinical Trials

NCT03786692

TH-138: Phase II Randomized Trial of Carboplatin = Pemetrexed + Bevaciumab, with or without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or have never Smoked

This study is currently enrolling.

The purpose of this research study is to determine if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in never smoker and sensi ...

NCT04746924

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

This study is currently enrolling.

This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...

NCT04613596

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This study is currently enrolling.

The main purpose of this study is to evaluate the clinical activity of MRTX849 administered in combination with pembrolizumab in the first-line treatment setting to subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) with ...

NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

This study is currently enrolling.

This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC-392 is an antibody drug th ...

Mark A. Socinski, MD

Overview

Articles

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

['Poziotinib in Non-Small-Cell Lung Cancer Harboring', 'Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.']

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer ABOUND.sqm): A Phase III Randomized Clinical Trial

Education & Training

Education

Residency

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

TH-138: Phase II Randomized Trial of Carboplatin = Pemetrexed + Bevaciumab, with or without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or have never Smoked

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

Explore

Institutes